Key result
MSC administration reduced cumulative PAH morbidity and attenuated endothelial damage, plexiform lesions, and inflammatory mediators in an avian model of pulmonary arterial hypertension.
Why the study?
Rodent models of PAH do not recapitulate all human histopathological features, whereas broiler chickens spontaneously develop strikingly similar neointimal and plexogenic arteriopathy.
Does MSC transplantation reduce PAH morbidity and right ventricular hypertrophy in an avian model of pulmonary arterial hypertension?
Does MSC transplantation reduce PAH morbidity and right ventricular hypertrophy in an avian model of pulmonary arterial hypertension?
MSC transplantation attenuates the development of pulmonary arterial hypertension in a broiler chicken model by modulating inflammation and enhancing endogenous MSC-mediated vascular repair.
Hypothesis-generating for MSC therapy in PAH; leaves open translation from avian models to humans.
Purpose: Pulmonary arterial hypertension (PAH) is a progressive and fatal pulmonary vascular disease initiated by endothelial dysfunction. Mesenchymal stromal cells (MSCs) have been shown to ameliorate PAH in various rodent models; however, these models do not recapitulate all the histopathological alterations observed in human PAH. Broiler chickens ( Gallus gallus ) can develop PAH spontaneously with neointimal and plexogenic arteriopathy strikingly similar to that in human patients. Herein, we examined the protective effects of MSC transplantation on the development of PAH in this avian model. Methods: Mixed-sex broilers at 15 d of age were received 2× 10 6 MSCs or PBS intravenously. One day later, birds were exposed to cool temperature with excessive salt in their drinking water to induce PAH. Cumulative morbidity from PAH and right-to-left ventricle ratio were recorded. Lung histologic features were evaluated for the presence of endothelial damage, endothelial proliferation and plexiform lesions. Expression of proinflammatory mediators and angiogenic factors in the lung was detected. Matrigel tube formation assay was performed to determine the angiogenic potential of endogenous MSCs. Results: MSC administration reduced cumulative PAH morbidity and attenuated endothelial damage, plexiform lesions and production of inflammatory mediators in the lungs. No significant difference in the expression of paracrine angiogenic factors including VEGF-A and TGF-β was determined between groups, suggesting that they are not essential for the beneficial effect of MSC transplantation. Interestingly, the endogenous MSCs from birds receiving MSC transplantation demonstrated endothelial differentiatial capacity in vitro whereas those from the mock birds did not. Conclusion: Our results support the therapeutic use of MSC transplantation for PAH treatment and suggest that exogenous MSCs produce beneficial effects through modulating inflammation and endogenous MSC-mediated vascular repair. Graphical Abstract: Keywords: plexiform lesion, right ventricular hypertrophy, VEGF-A, TGF-β, angiogenesis, bone marrow
No takes yet. Share an insight, caveat, or question.
Shao et al. (2022) studied Pulmonary arterial hypertension. MSC transplantation vs. PBS was evaluated on Cumulative morbidity from PAH and right-to-left ventricle ratio. MSC administration reduced cumulative PAH morbidity and attenuated endothelial damage, plexiform lesions, and inflammatory mediators in an avian model of pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: